HOOK News and Press, HOOKIPA Pharma Inc. From 11/20/23

2023-11-20 10:17:26 ET Whether you’re looking at the “ Magnificent Seven stocks ,” or just the next round of penny stocks to watch, news & company events can quickly sway sentiment. This week is a short holiday week with Thursday’s Thanksgivin...

Novel arenaviral therapeutic vaccine, developed in collaboration with Gilead Sciences, Inc. (‘Gilead’), to be evaluated as a potential curative regimen for human immunodeficiency virus (HIV) Phase 1 trial to commence in the first half of 2024 Nature Partner Jo...

2023-11-09 07:08:31 ET More on HOOKIPA Pharma Seeking Alpha’s Quant Rating on HOOKIPA Pharma Historical earnings data for HOOKIPA Pharma Financial information for HOOKIPA Pharma For further details see: HOOKIPA Pharma GAAP EPS of -$0.17 beats by $0...

Reported positive preliminary Phase 2 data on additional patients for HB-200 in combination with pembrolizumab in the 1 st -line setting for advanced HPV16+ head and neck cancer; data reinforce strong objective response rate and disease control rate reported in Q2 2023; randomized trial ...

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...

HOOKIPA Pharma Inc. (HOOK) is expected to report $-0.23 for Q3 2023

HB-200 monotherapy induced a robust increase in circulating tumor-specific CD8+ T cells in all evaluable Phase 1 patients with heavily pretreated HPV16+ head and neck cancer T cell responses were high quality, durable and suggest an association with clinical benefit based on disease contr...

NEW YORK and VIENNA, Austria, Nov. 02, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release its third quarter 2023 financial r...

42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line setting —doubling historical ORR reported with pembrolizumab alone 1 Strong immunogenicity and activation of ...

HB-400, a novel arenaviral therapeutic vaccine, generates robust T cell responses specific to hepatitis B virus with high antibody levels in a preclinical setting A Gilead-led Phase 1 clinical trial to evaluate the safety and tolerability of HB-400 in humans is ongoing Peer-review...